hackint0sh/New-Dataset huggingface dataset:
Can novel markers in ECG and echocardiography suggest the presence of PH? Can existing screening guidelines be improved with the addition of these markers? conditions: Pulmonary Hypertension studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 2500 type: ESTIMATED name: Electrocardiogram name: Transthoracic echocardiogram name: Right heart catheter measure: Distinguish between patients with and without pulmonary hypertension measure: Distinguish between patients with pre-capillary hypertension and post-capillary hypertension measure: Assess the impact of the severity of pulmonary hypertension measure: Assess the impact of additional ECG markers on existing PH probability stratification sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Royal United Hospital NHS Foundation Trust city: Bath state: Banes zip: BA1 3NG country: United Kingdom lat: 51.3751 lon: -2.36172 facility: Golden Jubilee Hospital city: Glasgow state: Lanarkshire zip: G81 4DY country: United Kingdom lat: 55.86515 lon: -4.25763 facility: Sheffield Teaching Hospitals NHS Foundation Trust city: Sheffield state: South Yorkshire zip: S10 2JF country: United Kingdom lat: 53.38297 lon: -1.4659 facility: Royal Papworth Hospital city: Cambridge zip: CB2 0AY country: United Kingdom lat: 52.2 lon: 0.11667 facility: Royal Free NHS Foundation Trust city: London zip: NW3 2QG country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06386172 id: 2023-03537-01 id: FoUI-986028 type: OTHER_GRANT domain: ALF Medicin, Region Stockholm briefTitle: Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm acronym: ALMA-CKD overallStatus: RECRUITING date: 2023-09-09 date: 2025-04 date: 2026-12 date: 2024-04-26 date: 2024-04-26 name: Karolinska Institutet class: OTHER name: Danderyd Hospital name: Region Stockholm briefSummary: One in 10 adults in Region Stockholm have chronic kidney disease (CKD), which dramatically increases healthcare costs and the risk of medication errors or adverse health outcomes, including cardiovascular disease and death. Identification and early management of these patients is done in primary care settings. However, most adults with CKD in our region are under detected, undiagnosed and undertreated, with low rates of referral to nephrology-specialist care.
As a pragmatic trial there is no active recruitment or active data collection. The trial is embedded into the ongoing Stockholm CREAtinine Measurements (SCREAM) project, a database collection of healthcare use for the complete population of Stockholm. Using this real-world healthcare data collection, the investigators will be able to measure with precision the impact of our CDS trigger and its potential to improve clinical care. conditions: Chronic Kidney Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The primary healthcare network system of the region of Stockholm coordinates 66 public primary healthcare centers. Collectively, these centers offer care to an estimated population of 780.000. Since November 2022, a new platform for CDS (clinical decision support) triggers called ALMA has been implemented in these centers. ALMA is connected to patient records and uses CDS triggers to identify medical problems, issue alerts and propose solutions.
Objective 2: to evaluate the effectiveness of this CDS trigger (versus current basic advice) through a 2-arm pragmatic cluster RCT. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 780000 type: ESTIMATED name: Clinical decision support trigger measure: Number of participants screened for creatinine and albuminuria measure: Number of screened participants with retesting for creatinine and albuminuria measure: Number of participants with laboratory-determined CKD receiving a clinical diagnosis measure: Number of participants receiving CKD-modifying agents measure: Number of participants referred to nephrologist care sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Karolinska Institutet status: RECRUITING city: Stockholm country: Sweden name: Juan J Carrero, Prof role: CONTACT phone: 0046739636948 email: juan.jesus.carrero@ki.se lat: 59.33258 lon: 18.0649 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2024-04-01 uploadDate: 2024-04-23T02:35 filename: SAP_000.pdf size: 292236 hasResults: False
nctId: NCT06386159 id: 2023-1178 briefTitle: Clinical Application of Comprehensive Intervention for PED Based on Neuroregulatory Mechanism overallStatus: RECRUITING date: 2024-03-15 date: 2025-04-30 date: 2025-07-30 date: 2024-04-26 date: 2024-04-26 name: Second Affiliated Hospital, School of Medicine, Zhejiang University class: OTHER briefSummary: This study aims to establish a practical comprehensive intervention program for dysphagia after extubation in adult ICU patients based on the best evidence of its assessment and intervention, through expert panel discussion and Delphi method. In addition, combining the preliminary experimental results of vagus nerve stimulation applied to PED patients, we further develop a comprehensive intervention program for dysphagia after extubation based on neural regulation mechanism. Finally, the implementation effect of this PED comprehensive intervention program based on neural regulation mechanism will be verified through clinical application. conditions: Post-extubation Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 69 type: ESTIMATED name: Electrical vagus nerve stimulation measure: functional oral intake scale（FOIS） measure: standardized Swallowing Assessment（SSA） measure: Rate of total oral feeding after the intervention measure: Duration of Enteral Nutrition Tube Indwelling measure: Rate of Re-intubation after Endotracheal Intubation measure: Incidence of aspiration within one week after extubation measure: The incidence of aspiration pneumonia within one week after extubation measure: Inflammation-related indicators: serum C-reactive protein (CRP) measure: Inflammation-related indicators: serum interleukin-6 (IL-6) measure: Inflammation-related indicators: serum procalcitonin, acetylcholine (ACh) measure: Inflammation-related indicators: high mobility group box-1 protein (HMGB1) measure: Days of ICU hospitalization measure: Total days of hospitalization measure: In-hospital survival rate sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Feng Xiuqin status: RECRUITING city: Hangzhou zip: 310000 country: China name: Feng Feng, Xiuqin role: CONTACT phone: 13757119151 email: fengxiuqin@zju.edu.cn lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06386146 id: JAB-30355-1001 briefTitle: JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-01 date: 2027-07 date: 2024-04-26 date: 2024-04-26 name: Jacobio Pharmaceuticals Co., Ltd. class: INDUSTRY briefSummary: This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation. conditions: Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 144 type: ESTIMATED name: JAB-30355 name: JAB-30355 measure: Dose limiting toxicity (DLT) measure: Number of participants with adverse events measure: Peak Plasma Concentration (Cmax) measure: Time to reach the observed maximum (peak) concentration (Tmax) measure: Terminal half-life (t1/2) measure: Objective response rate (ORR) measure: Duration of response (DOR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06386133 id: MS Boost briefTitle: Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care acronym: MSBoost overallStatus: NOT_YET_RECRUITING date: 2024-10-01 date: 2025-07-01 date: 2026-04-01 date: 2024-04-26 date: 2024-04-26 name: Ad scientiam class: OTHER name: Assistance Publique - Hôpitaux de Paris briefSummary: The main objective of the MS Boost study is to demonstrate the superiority of MSCopilot Boost over standard practice in reducing the impact of fatigue on Patients with Multiple Sclerosis (MS).
The secondary objectives include validating MSCopilot Boost clinical performance in reducing fatigue and its impact as well as evaluating its functional tests performance and its safety of use. The investigation team will also investigate the effects of MSCopilot Boost on patient symptoms, functional parameters and physical activity levels. The investigation team will evaluate patients and healthcare professionals' perceived clinical benefit as well as adherence, satisfaction and user experience related to the mobile application and the web portal. Ultimately, the investigation team will define the medico-economic and organizational impact of the MSCopilot Boost solution.
Healthcare professionals' expected benefits are to track objective measures of key functional symptoms of the disease between consultations, supporting MS patients' management and to gain time by providing a "big picture" of the patient's condition over time. conditions: Multiple Sclerosis conditions: Fatigue Syndrome, Chronic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Boost group: Use of MSCopilot Boost and wear of an actimeter during the whole study participation duration.
nctId: NCT06386120 id: 2024-z033 briefTitle: Respiratory Function Monitoring of Mechanical Ventilation in Patients With Chest Blunt Injury overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-07 date: 2024-04-26 date: 2024-04-26 name: Peking University People's Hospital class: OTHER briefSummary: The goal of this observational study is to learn about EIT in observing the application of lung protective ventilation strategies in patients with pulmonary contusion, particularly the impact on pulmonary ventilation blood flow ratio, oxygen, and condition. The main question it aims to answer is:
Can lung protective ventilation strategies improve respiratory function in patients with severe chest contusion? We will collect clinical data of participants who already taking lung protective ventilation strategies as part of their regular medical care. conditions: Lung Contusion studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: PEEP setting strategy measure: ventilation blood flow ratio measure: oxygenation index measure: 28-day mortality measure: Mechanical ventilation-free from day 1 to 28 measure: Length of ICU stay measure: Length of hospital stay measure: The rate of successful weaning sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06386107 id: 23PH188 id: 2023-A02175-40 type: OTHER domain: ANSM briefTitle: Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis acronym: CATforCAT overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-01 date: 2026-08 date: 2024-04-26 date: 2024-04-26 name: Centre Hospitalier Universitaire de Saint Etienne class: OTHER name: Diagnostica Stago name: LEO Pharma name: Ligue contre le cancer, France briefSummary: Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of bleeding in the first 6 months. Most of the guidelines propose to integrate the bleeding risk in the choice of therapies. Thrombin generation assay (TGA) reflects an overall hemostatic response and could be a useful biomarker. Proven on the thrombotic side in the CAT population, useful in the assessment of the bleeding risk of hemophiliac patients, the TGA is emerging as a tool. The investigators to measure TGA in cancer patients included prospectively, having recently developed a CAT and to evaluate the association between the measurement and the risk of hemorrhagic complication under anticoagulant during the first 6 month of treatment. conditions: Cancer conditions: Pulmonary Embolism conditions: Thrombosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective cohort of consecutive patients initiating full-dose anticoagulant therapy for an episode of CAT, followed up until the 6th month of treatment to assess the risk of clinically relevant adjunctive bleeding events and any other adverse event during anticoagulant therapy (recurrence of CAT, death).
TGT measurement is fully automated and calibrated with quality control. primaryPurpose: OTHER masking: NONE count: 212 type: ESTIMATED name: Thrombin Generation Assay (TGA) measure: The measurement of the area under the curve ( endogenious thrombin potential) nMxmin measure: the measurement of the lag time unit = seconds measure: the measurement of the peak height unit = nm measure: the measurement of the time to peak unit = seconds measure: Effect of adding TGT results on the performance of bleeding risk prediction scores measure: Occurrence of clinically relevant bleeding between m1 and m6, based on the change in TGT measure: Occurrence of an event of interest under treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chu Clermont-Ferrand city: Clermont-Ferrand zip: 63003 country: France name: Jeannot SCHMIDT, MD PHD role: CONTACT name: Jeannot SCHMIDT, MD PHD role: PRINCIPAL_INVESTIGATOR name: Aurélien LEBRETON, MD PHD role: SUB_INVESTIGATOR name: Fares MOUSTAFA, MD PHD role: SUB_INVESTIGATOR name: Nicolas DUBLANCHET, MD role: SUB_INVESTIGATOR name: Dorian TEISSANDIER, MD role: SUB_INVESTIGATOR lat: 45.77966 lon: 3.08628 facility: CHU de Grenoble city: Grenoble zip: 38043 country: France name: Gilles PERNOD, MD PHD role: CONTACT phone: 04 76 76 57 17 phoneExt: +33 email: gpernod@chu-grenoble.fr name: Gilles PERNOD, MD PHD role: PRINCIPAL_INVESTIGATOR name: Raphaël MARLU, MD PHD role: SUB_INVESTIGATOR lat: 45.16667 lon: 5.71667 facility: HCL city: Lyon country: France name: Yesim DARGAUD, MD PHD role: CONTACT name: Judith CATELLA, MD role: PRINCIPAL_INVESTIGATOR name: Claire GRANGE, MD role: SUB_INVESTIGATOR name: Yesim DARGAUD, MD PHD role: SUB_INVESTIGATOR lat: 45.74848 lon: 4.84669 facility: Chu St-Etienne city: Saint-Étienne zip: 42055 country: France name: Géraldine POENOU, MD PHD role: CONTACT email: geraldine.poenou@chu-st-etienne.fr name: Laurent BERTOLETTI, MD PHD role: SUB_INVESTIGATOR name: Xavier DELAVENNE, MD PHD role: SUB_INVESTIGATOR name: Coline LEGENDRE, MD role: SUB_INVESTIGATOR name: Pauline NOYEL, MD role: SUB_INVESTIGATOR name: Brigitte TARDY, MD PHD role: SUB_INVESTIGATOR name: Géraldine POENOU, MD PHD role: PRINCIPAL_INVESTIGATOR lat: 45.43389 lon: 4.39 hasResults: False
nctId: NCT06386094 id: INT/IEC/2023/SPL-902 briefTitle: Cardiac Dysfunction in Patients With Non-alcoholic Fatty Liver Disease overallStatus: RECRUITING date: 2023-07-15 date: 2025-08-15 date: 2025-11-15 date: 2024-04-26 date: 2024-04-26 name: Post Graduate Institute of Medical Education and Research, Chandigarh class: OTHER briefSummary: Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality. conditions: NAFLD conditions: Cardiac Disease conditions: Fatty Liver studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Echocardiographic assessment measure: To determine the prevalence of cardiac dysfunction in patients with non-alcoholic fatty liver disease measure: Presence of myocardial abnormalities in CCM dysfunction measure: Presence of perfusion abnormalities in CCM dysfunction measure: All cause mortality in NAFLD measure: Cardiac event related mortality in NAFLD measure: To determine the severity of cardiac dysfunction in patients with non-alcoholic fatty liver disease sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dr. Madhumita Premkumar status: RECRUITING city: Chandigarh zip: 160012 country: India name: Dr. Madhumita Premkumar, MD role: CONTACT phone: +9101722754777 email: drmadhumitap@gmail.com lat: 30.73629 lon: 76.7884 hasResults: False
nctId: NCT06386081 id: AC18/00031 briefTitle: Dietary Intervention in Food Allergy acronym: AC18/00031 overallStatus: COMPLETED date: 2021-01-01 date: 2023-01-31 date: 2023-06-30 date: 2024-04-26 date: 2024-04-26 name: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud class: OTHER briefSummary: The goal of this randomized double-blind placebo-controlled clinical study is to determine whether the dietary intervention with pectins leads to food immunomodulation in non-specific lipid transfer proteins (nsLTP) allergic patients. The main question it aims to answer is if the microbiome is a target of intervention against food allergy through the use of prebiotics such as pectins.
Participants will be enrolled to receive a two-month dietary intervention with either two different pectins (citrus or apple pectin) or placebo. Increase in oral tolerance to the peach nsLTP will be measured through a double-blind placebo-controlled food challenge (DBPCFC). Microbiome, proteomic and metabolomic studies will also be performed in blood and stool samples. conditions: Food Allergy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Treatment will be blinded to the participants and research team. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 51 type: ACTUAL name: Citrus pectin with low DE name: Apple pectin with high DE name: Placebo measure: Clinical efficacy of pectin dietary intervention in nsLTP allergic patients measure: Changes in Pru p 3 (nsLTP of peach) specific IgE production induced by pectin intervention measure: Pru p 3-specific maturational changes of dendritics cells induced by pectin intervention measure: Pru p 3-specific proliferative response of different lymphocytes cell subpopulations after pectin intervention measure: Changes in Pru p 3-specific basophil activation induced by pectin intervention measure: Changes induced in the taxonomic diversity of gut microbiota measure: Changes in feaces metabolome induced by pectin dietary intervention measure: Changes in serum metabolome induced by the pectin dietary intervention measure: Epigenomic changes induced by the pectin dietary intervention measure: Pectin safety profile sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Hospital Regional Universitario de Málaga city: Malaga country: Spain lat: 36.72016 lon: -4.42034 hasResults: False
nctId: NCT06386068 id: 2110041 briefTitle: Interdisciplinary Value-based Cognitive Behavioral Treatment for People With Persistent Whiplash Associated Disorders. acronym: VALIANT overallStatus: RECRUITING date: 2024-01-23 date: 2024-06 date: 2024-06 date: 2024-04-26 date: 2024-04-26 name: University of Southern Denmark class: OTHER briefSummary: The goal of this clinical trial is to address the critical need for effective interventions by developing and testing an interdisciplinary values-based cognitive behavioral therapy (V-CBT) program for individuals with persistent whiplash. The main question it aims to answer are:
Participants will undergo a replicated multiple baselines single-case experimental design (SCED). Twelve participants who meet specific eligibility criteria will be block-randomized to a 1, 2, or 3-week baseline phase, serving as their own controls. The intervention involves an interdisciplinary team delivering a manualized adapted V-CBT program over ten sessions, focusing on psychological and physical rehabilitation. Participants will be required to attend these sessions as part of the treatment protocol. Data collection includes daily online self-reports and comprehensive measurements at pre-treatment, post-treatment, and a three-month follow-up. conditions: Whiplash Injuries studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A replicated multiple baselines single-case experimental design with three baseline phases. Baseline randomization into three tiers. primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Values-based Cognitive Behavioral Therapy (V-CBT) measure: Value-based living measure: Pain interference measure: Value-based living measure: Pain interference measure: Pain catastrophizing measure: Positive affect measure: Negative affect measure: Stress measure: Fatigue measure: Pain-related acceptance measure: Pain-related self-efficacy measure: Pain severity measure: Neck Disability measure: Depression measure: Anxiety measure: Stress measure: Health-related quality of life measure: Pain-related acceptance measure: Pain-related self-efficacy measure: Sleep quality measure: Pain severity measure: Self-perceived improvement measure: Satisfaction with treatment measure: Pain Disability sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Specialized Hospital for Polio and Accident Victims status: RECRUITING city: Rødovre state: Capital Region Of Denmark zip: 2610 country: Denmark name: Anders O Aaby, PhD role: CONTACT email: aaa@specialhospitalet.dk lat: 55.68062 lon: 12.45373 hasResults: False
nctId: NCT06386055 id: STUDY00007545 briefTitle: Air Pollution and Physical Activity: A Randomized Controlled Trial acronym: PARC overallStatus: NOT_YET_RECRUITING date: 2024-06-15 date: 2024-10-15 date: 2024-12-01 date: 2024-04-26 date: 2024-04-26 name: State University of New York at Buffalo class: OTHER briefSummary: This is a small pilot intervention trial in which we will collect preliminary data to demonstrate the feasibility of an intervention study. conditions: Physical Inactivity conditions: Pollution; Exposure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 24 type: ESTIMATED name: Active exercise measure: blood pressure measure: Self-report questionnaire sex: ALL minimumAge: 35 Years maximumAge: 55 Years stdAges: ADULT facility: University at Buffalo city: Buffalo state: New York zip: 14214 country: United States lat: 42.88645 lon: -78.87837 hasResults: False